Randomized trial demonstrates reduced restenosis rates in patients with coronary artery disease, suggesting improved stent safety.
As compared with bare-metal stents, the slow-release, polymer-based, paclitaxel-eluting stent is safe and markedly reduces the rates of clinical and angiographic restenosis at nine months.
No takes yet. Share an insight, caveat, or question.
Stone et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: